MedTrace Logo

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

NCT02341456 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-03-25

Study results available
· View outcomes & findings →

Summary

This is a phase Ib, open-label, multicentre study of AZD1775 administered orally in monotherapy and in combination with carboplatin and paclitaxel to Asian patients with advanced solid tumours.

Conditions

  • Advanced Solid Tumours

Interventions

DRUG

AZD1775

AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.

DRUG

Paclitaxel

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy ; it and docetaxel represent the taxane family of drugs.

DRUG

carboplatin

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).

Sponsors & Collaborators

Principal Investigators

  • Dr. Paul De Souza, MD · Liverpool Hospital, New South Wales

  • Dr. Jason Lickliter, MD · Nucleus Network Limited, Victoria

  • Dr. Noboru Yamamoto, MD · NCC Hospital

  • Dr Toshihiko Doi, MD · NCC Hospital (East)

  • Prof Yung Ju Bang · Seoul National University Hospital

  • Prof Sang Prof Sang · Asan Medical Centre

  • Prof Keunchil Park · Samsung Medical Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-16
Primary Completion
2016-12-14
Completion
2018-07-09

Countries

  • Australia
  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02341456 on ClinicalTrials.gov